Supporting data for "Therapeutic and Drug Resistance Mechanisms of Quizartinib and Omacetaxine Mepasuccinate (QUIZOM) in FLT3-ITD Acute Myeloid Leukemia"

We examined the therapeutic mechanisms of Quizartinib and Omacetaxine Mepesuccinate (QUIZOM) in FLT3-ITD AML. The results of Cancer Dependency Map (DepMap) and RNA sequencing data analysis were provided here. Specifically, we compared FLT3-ITD AML cell lines versus FLT3-wildtype AML cell lines in terms of gene knock-out effect and identified key pathways that FLT3-ITD AML cells depended on by gene set enrichment analysis (GSEA). In-vitro treatment of Quizartinib and Omacetaxine Mepesuccinate was conducted in MOLM13 and MV4-11 cell lines, and RNA-seq data was analyzed for differentially expressed genes (DEGs) and pathway enrichment.

本研究深入探讨了Quizartinib和Omacetaxine Mepesuccinate（QUIZOM）在FLT3-ITD急性髓系白血病（AML）中的治疗机制。在此，我们提供了癌症依赖性图谱（DepMap）以及RNA测序数据分析的结果。具体而言，我们对比了FLT3-ITD AML细胞系与FLT3野生型AML细胞系在基因敲除效应方面的差异，并通过基因集富集分析（GSEA）确定了FLT3-ITD AML细胞所依赖的关键通路。在MOLM13和MV4-11细胞系中进行了Quizartinib和Omacetaxine Mepesuccinate的体外治疗，并对差异表达基因（DEGs）和通路富集进行了RNA测序数据分析。